- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06519539
Implementing Strategies for Eating Behaviour Modification Based on Portion Control (PORTIONS-4)
July 24, 2024 updated by: Clinica Universidad de Navarra, Universidad de Navarra
Implementing Strategies for Eating Behaviour Modification Based on Portion Control: Methodological Development and Pilot Study
This is a pre-post intervention study designed to evaluate the feasibility of a self-applied weight management intervention based on portion control.
A total of 40 healthy volunteers with overweight/obesity will take part in a 6-month intervention featuring 4 components: a portion control toolset; a manual including instructions for the use of the tools, dietary and activity recommendations, and behavioural strategies; a mobile app to motivate intervention engagement; and biweekly telephone support.
The primary outcome will be Intervention adherence, assessed as the change in dietary energy density, meal nutrient composition and utilization of intervention components from start to end of trial.
Other measurements (at baseline, 3 and 6 months from baseline) will include body composition, fasting biochemical parameters, inhibitory control, eating behaviour, portions size norms and acceptance of the intervention.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
According to recent meta-analyses, portion control tools represent an acceptable and potentially effective strategy to aid in weight loss.
However, how well these tools work depends on their consistent use and a good integration with other lifestyle modification strategies around body weight control and overall health.
The present pilot study was designed to evaluate the feasibility of a self-applied weight management intervention based on portion control and to identify factors influencing adherence.
The sample will consist of 40 healthy volunteers with overweight/obesity who will engage in a pre-post intervetion study lasting six-months.
The intervetion will include four components: (1) a portion control toolkit (serving spoon and oil dispenser); (2) a phsyical manual with instructions for using the tools, dietary and physical activity recommendations, and strategies to build habits and improve mental wellbeing; (3) a mobile app to motivate intervention engagement; and (4) biweekly short telephone support.
Adherence to the intervention will be the primary outcome, assessed on a fortnightly basis as the change from baseline in dietary energy density and change in meal nutrient composition plus frequency of using the intervention components.
Other measurements that will be taken at baseline, 3 and 6 months from baseline, will be: body composition, fasting biochemical parameters, inhibitory control (only baseline and 6 months), eating behaviour, portion size norms and intervention acceptance.
After 3 months of taking part in the intervention, a subset of the sample will participate in a nominal group session aimed at identifying barriers to intervention adherence and strategies to overcome them.
The study results will inform the design of a full-scale controlled trial featuring the most successful components.
Study Type
Observational
Enrollment (Actual)
40
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- University of Navarra, Dept. of Food Science and Physiology, Center for Nutrition Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Healthy men and women living with overweight or obesity and willing to receive a 6-month intervention focused on changing their dietary habits
Description
Inclusion Criteria:
- Body mass index equal or above 27.5 kg/m2 (26.0 kg/m2 for those of Asian descent)
- Eating home-made meals at least 5 days a week
- Physically and mentally fit as assessed by the study researcher
- On-going pharmacological and hormonal treatment is accepted when this does not affect the study parameters (e.g. glucose response, appetite), and when the participant has been in a stable dose for at least 3 months
- Agreeing to undergo all the study procedures
- Being able to attend in person on 3 clinical investigation days during working hours
- Being able to understand and agree to sign the informed consent form
Exclusion Criteria:
- Being a regular smoker (that is, smoke more than 4 cigarettes a month)
- Being pregnant, breastfeeding or planning a pregnancy
- Exceed the alcohol consumption limit marked for the corresponding sex (more than 14 units in women and 20 units in men)
- Having followed a meal plan for weight loss and/or muscle mass gain in the 3 months prior to the start of the study intervention
- Having used a portion measuring instrument (e.g. scale, calibrated plate, etc.) consistently (at least in one main meal for at least 5 days a week) during the 3 months prior to the start of the study intervention
- Experiencing a weight change greater than 5% in the last 3 months
- History of relevant functional or structural anomalies of the digestive system, such as malformations, angiodysplasias, active peptic ulcers, chronic inflammatory or malabsorption diseases, or history of intestinal or bariatric surgery
- Suffer from some type of cancer, currently undergoing treatment for cancer, or when a period of at least 5 years has not elapsed since its eradication
- On-going chronic metabolic disease or obesity-related disease, or any systemic intestinal, liver or kidney disease such as type 1 or type 2 diabetes, severe dyslipidemia, uncontrolled thyroid function disorder, cirrhosis, inflammatory bowel disease, untreated anemia, etc. . (will not be excluded due to "fatty liver")
- Avoiding, being allergic, or being intolerant to the study foods or their ingredients (lactose free and regular chocolate milkshake)
- History of anaphylactic reaction to any food
- Taking any nutritional supplementation as a prescription medication that may affect the results of the study
- Taking over-the-counter nutritional supplementation (that is, without a medical prescription) that may affect the results of the study, unless the person is willing to stop it during the 6 months of the study duration and only when a minimum washout period of 14 days can be guaranteed prior to the basal measurements being taken
- A high incidence of attitudes and behaviors associated with eating disorders, expressed as a score greater than 20 on the 26-item Eating Attitudes Test scale (EAT - 26)
- Co-inhabiting with a study participant
- For former PORTIONS-3 study participants, when less than 3 months have passed since the last intervention visit (accepted if 3 or more months have elapsed).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Adults with overweight or obesity
Healthy adults with a BMI of 27.5 kg/sq-m or above (26 or above for those of Asian descent), who will undertake a 6 month lifestyle intervention focused on improving dieary choices, physical activity and attitudes towards weight management.
|
The intervention includes 4 components, including: a portion control tool set previously developed and tested in our laboratory; a supporting guide (physical book) with dietary, activity and behavioural recommendations; a mobile application aligned with the guide; and biweekly telephone calls from the psychologist and/or dietitian.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in 24 h total dietary energy intake
Time Frame: Clinical investigation day 1 (week 0); Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
24 h total dietary energy intake (in kcal) will be obtained from the 24 h dietary record
|
Clinical investigation day 1 (week 0); Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
|
Change from baseline in 24 h total dietary volume intake
Time Frame: Clinical investigation day 1 (week 0); Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
24 h total dietary volume intake (in g) will be obtained from the 24 h dietary record
|
Clinical investigation day 1 (week 0); Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
|
Change from baseline in daily dietary energy density
Time Frame: Clinical investigation day 1 (week 0); Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
24 h total dietary energy intake (kcal) and 24 h total dietary volumen intake (g) will be combined to report daily dietary energy density (in kcal/g).
Daily dietary energy density is defined as the ratio of 24 h total dietary energy intake (in kcal) to the 24 h total dietary volume intake (in g)
|
Clinical investigation day 1 (week 0); Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
|
Intervention adherence
Time Frame: Clinical investigation day 1 (week 0); Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
Daily dietary energy density, meal nutrient composition and use of intervention components (spoon, oil dispenser, guide, app) will be combined to report intervention adherence (as a qualitative measure)
|
Clinical investigation day 1 (week 0); Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in meal dietary energy density
Time Frame: Clinical investigation day 1 (week 0); Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
Meal (breakfast, lunch and dinner) dietary energy density (kcal/g) will be calculated as the ratio of meal total dietary energy intake (in kcal) to the 24 h total dietary volume intake (in g), obtained from the 24 h dietary record
|
Clinical investigation day 1 (week 0); Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
|
Change from baseline in meal nutrient composition: Grams
Time Frame: Clinical investigation day 1 (week 0); Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
Meal (breakfast, lunch and dinner) nutrient content (in g) will be defined as the meal's content of carbohydrate (g), protein (g), vegetables (g), fibre (g), and sodium (mg) obtained from the 24 h dietary record
|
Clinical investigation day 1 (week 0); Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
|
Change from baseline in meal nutrient composition: % energy
Time Frame: Clinical investigation day 1 (week 0); Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
Percent of daily energy from meals will be defined as the % energy provided by carbohydrate, protein and vegetables at each meal (breakfast, lunch and dinner), obtained from the 24 h dietary record
|
Clinical investigation day 1 (week 0); Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
|
Use of serving spoon (24 h frequency)
Time Frame: Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
Number of times the intervention spoon has been used in a period of 24 h
|
Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
|
Use of oil dispenser (24 h frequency)
Time Frame: Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
Number of times the intervention oil dispenser has been used in a period of 24 h
|
Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
|
Use of intervention guide (24 h frequency)
Time Frame: Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
Number of times the intervention guide has been consulted in a period of 24 h
|
Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
|
Use of intervention app (24 h frequency)
Time Frame: Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
Number of times the intervention app has been used in a period of 24 h
|
Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
|
Use of serving spoon (15 day frequency)
Time Frame: Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
Number of times the intervention spoon has been used in a period of 15 days
|
Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
|
Use of oil dispenser (15 day frequency)
Time Frame: Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
Number of times the intervention oil dispenser has been used in a period of 15 days
|
Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
|
Use of intervention guide (15 day frequency)
Time Frame: Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
Number of times the intervention guide has been consulted in a period of 15 days
|
Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
|
Use of intervention app (15 day frequency)
Time Frame: Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
Number of times the intervention app has been used in a period of 15 days
|
Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
|
Anthropometric profile: Change from baseline in Body Weight
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
Weight will be measured in kg; Weight and height will be combined to report BMI in kg/m^2
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
|
Anthropometric profile: Body Height
Time Frame: Clinical investigation day 1 (week 0)
|
Height will be measured in m using a stadiometer; Weight and height will be combined to report BMI in kg/m^2
|
Clinical investigation day 1 (week 0)
|
|
Anthropometric profile: Change from baseline in Body Mass Index
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
Weight and height will be combined to report BMI in kg/m^2
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
|
Anthropometric profile: Change from baseline in Waist circumference
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
Waist circumference will be measured in cm using a measuring tape.
Waist circumference and hip circumference will be combined to report Waist-to-hip ratio.
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
|
Anthropometric profile: Hip circumference
Time Frame: Clinical investigation day 1 (week 0)
|
Hip circumference will be measured in cm using a measuring tape.
Waist circumference and hip circumference will be combined to report Waist-to-hip ratio.
|
Clinical investigation day 1 (week 0)
|
|
Anthropometric profile: Change from baseline in Waist-to-hip ratio
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
Waist circumference and hip circumference will be combined to report Waist-to-hip ratio.
Waist to hip ratio is defined as the ratio of the waist circumference (cm) to the hip circumference (cm)
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
|
Anthropometric profile: Change from baseline in body fat composition
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
Body fat composition will be quantified as fat mass (in kg, %) from a body composition analyser
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
|
Biochemical profile: Change from baseline in fasting blood glucose
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
Fasting blood glucose levels (mg/dL)
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
|
Biochemical profile: Change from baseline in fasting blood insulin
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
Fasting blood insuliln levels (mIU/L)
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
|
Biochemical profile: Change from baseline in fasting blood triglycerides
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
Fasting blood triglycerides levels (mg/dL)
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
|
Biochemical profile: Change from baseline in fasting blood cholesterol
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
Fasting blood total cholesterol levels (mg/dL)
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
|
Biochemical profile: Change from baseline in fasting blood ghrelin
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
Fasting blood total ghrelin levels (pg/mL)
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
|
Biochemical profile: Change from baseline in fasting blood leptin
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
Fasting blood leptin levels (ng/mL)
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
|
Meal eating behaviour: Change from baseline in Eating rate
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
Average amount of milkshake consumed per unit of time (g/min), based on validated methodology (Yeomans, 2000)
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
|
Meal eating behaviour: Change from baseline in bite size
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
Average amount of milkshake consumed at each sip (g), based on validated methodology (Yeomans, 2000)
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
|
Meal eating behaviour: Change from baseline in meal duration
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
Average time used to drink a milkshake (min), based on validated methodology (Yeomans, 2000)
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
|
Meal eating behaviour: Change from baseline in deceleration rate
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
Average change in eating rate (g/sec-squared), based on validated methodology (Yeomans, 2000)
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
|
Inhibitory control pattern: Change from baseline in N200 wave latency
Time Frame: Clinical investigation day 1 (week 0), clinical investigation day 3 (week 24)
|
N200 wave latency (milisec), based on the Go/No Go paradigm (Ochner et al., 2009)
|
Clinical investigation day 1 (week 0), clinical investigation day 3 (week 24)
|
|
Inhibitory control pattern: Change from baseline in N200 wave length
Time Frame: Clinical investigation day 1 (week 0), clinical investigation day 3 (week 24)
|
N200 wave length (microV), based on the Go/No Go paradigm (Ochner et al., 2009)
|
Clinical investigation day 1 (week 0), clinical investigation day 3 (week 24)
|
|
Inhibitory control pattern: Change from baseline in P300 wave latency
Time Frame: Clinical investigation day 1 (week 0), clinical investigation day 3 (week 24)
|
P300 wave latency (milisec), based on the Go/No Go paradigm (Ochner et al., 2009)
|
Clinical investigation day 1 (week 0), clinical investigation day 3 (week 24)
|
|
Inhibitory control pattern: Change from baseline in P300 wave length
Time Frame: Clinical investigation day 1 (week 0), clinical investigation day 3 (week 24)
|
P300 wave length (microV), based on the Go/No Go paradigm (Ochner et al., 2009)
|
Clinical investigation day 1 (week 0), clinical investigation day 3 (week 24)
|
|
Learning task: Change from baseline in learned meal portion size
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
% error in chosen portion sizes for starch, protein and vegetables of a virtual meal vs recommended portion sizes (based on Brunstrom & Rogers, 2009)
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
|
Learning task: Change from baseline in learned meal nutrient content
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
% error in chosen nutrient content of a virtual meal vs recommended nutrient content (based on Brunstrom & Rogers, 2009)
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Socio-demographic and lifestyle data
Time Frame: Pre-screening
|
Socio-demographic characteristics of the sample collected via self-reported questionnaire (age, sex, education, marital status, household composition, employment, physical activity level, smoking, alcohol intake)
|
Pre-screening
|
|
Eating habits: Risk of eating disorders
Time Frame: Pre-screening
|
Score in the Eating Attitudes Test-26, ranging from 0-78 points, validated by Garner et al., 1982.
Scores above 20 suggest risk for presence of potential eating disorders.
|
Pre-screening
|
|
Eating habits: Eating habits profile
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
Profile defined by the combined Restraint (0-21 points), Disihnibition (0-16 points) and Susceptibilty to hunger (0-14 points) sub-scales scores of the Three Factor Eating Questionnaire (TFEQ), validated by Stunkard & Messick, 1985.
Restraint values above 11, disinhibition values above 8 and susceptibility to hunger values above 4 are considered worse outcomes (i.e.
risk for development of obesity and other eating disorders)
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
|
Eating habits: Portion control tool usage
Time Frame: Clinical investigation day 3 (week 24)
|
Previous usage of portion control tools (end of study interview)
|
Clinical investigation day 3 (week 24)
|
|
Eating habits: Frequency of home made meals
Time Frame: Pre-screening
|
Frequency of consuming home made meals via self-reported questionnaire
|
Pre-screening
|
|
Eating habits: Frequency of take away meals
Time Frame: Pre-screening
|
Frequency of consuming take away meals via self-reported questionnaire
|
Pre-screening
|
|
Eating habits: Meal prep and serving
Time Frame: Pre-screening
|
Responsible person for cooking at home, via self-reported questionnaire
|
Pre-screening
|
|
Eating habits: Liking for the intervention food (milkshake)
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
Liking for the foods to be used in the intervention, via self-reported questionnaire (100 mm visual analogue scale)
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
|
Eating habits: Familiarity with the intervention food (milkshake)
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
Familiarity with the foods to be used in the intervention, via self-reported questionnaire (100 mm visual analogue scale)
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
|
Eating habits: Appetite levels
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
Scores for hunger, fullness, thirst, prospective intake, nausea measured on a 100 mm visual analogue scale before consumption of a milkshake (validated questionnaire based on Hill & Blundell, 1982)
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
|
Eating habits: Beverage consumption habits
Time Frame: Pre-screening (week 0), clinical investigation day 3 (week 24)
|
Self-reported questionnaire assessing caloric beverage intake, awareness of beverage portion sizes and acceptance of portioning tools for liquids currently on the market (pre-piloted on-line BPS survey, Vargas-Alvarez et al., 2021)
|
Pre-screening (week 0), clinical investigation day 3 (week 24)
|
|
Eating habits: Problem eating behaviour questionnaire (PEBQ)
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
Validated questionnaire (Carter & Jansen, 2012) used to identify eating patterns associated with the risk for obesity.
It consists of 25 items answered on a 5-Pt intensity scale.
The information collected can be used qualitatively, to identify problematic behaviors, or quantitatively by adding the direct scores.
Scores greater than 50 suggest a moderate to high frequency of behaviors associated with obesity.
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
|
Medical history
Time Frame: Pre-screening (week 0)
|
Self-reported questionnaire based on previous studies (Almiron-Roig et al., 2023) asking about special dietary needs, pregnancy, lactation, menopause, history of eating disorders, history of mental illness, incompatible medical conditions (e.g.
cancer, diabetes, memory loss), regular medication including nutritional and other supplements
|
Pre-screening (week 0)
|
|
Anthropometric profile: General body composition
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
Fat mass distribution (trunk, arms, legs), fat-free mass (kg, %), fat-free mass distribution, basal metabolic rate (kcal/day)
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), clinical investigation day 3 (week 24)
|
|
Psychological profile: Personality
Time Frame: Pre-screening
|
Score in the NEO-Five Factor Inventory (NEO-FFI) 60 item validated questionnaire (Costa & McCrae, 1989).
The score for each central domain of normal personality defined by the Five-Factor Model of personality (neuroticism, extraversion, conscientiousness, agreeableness, and openness to experience) is calculated.
A higher score on a scale assessing a certain personality domain indicates a stronger expression of traits associated with this particular domain
|
Pre-screening
|
|
Psychological profile: Perceived stress
Time Frame: Pre-screening
|
Score in the Perceived Stress Scale-14 (PSS-14) validated questionnaire (Cohen et al., 1983).
Scores ranging from 0 to 13 suggest low stress, scores ranging from 14 to 24 suggest moderate stress, and scores above 27 suggest high perceived stress
|
Pre-screening
|
|
Psychological profile: Emotional intelligence
Time Frame: Pre-screening
|
Score in the Trait Meta-Mood Scale-24 (TMMS-24) validated questionnaire (Salovey et al., 1995).
The score for three different dimensions of emotional intelligence are calculated.
To obtain a score for each factor, items 1 to 8 are added for the emotional attention factor, items 9 to 16 for the emotional clarity factor, and items 17 to 24 for the emotional repair factor.
|
Pre-screening
|
|
Psychological profile: Mood
Time Frame: Pre-screening
|
Score in the Profile of Mood States (POMS) validated questionnaire (McNair et al., 1971).
The score for six different dimensions of mood (tension, anger, fatigue, depression, confusion, and vigour) is calculated.
A higher score on a scale assessing a certain mood dimension indicates a stronger expression of associated feelings.
The resulting scores will range from -24 to 177, with lower scores indicative of people with more stable mood profiles
|
Pre-screening
|
|
Attitude towards intervention: Intervention expectations
Time Frame: Clinical investigation day 1 (week 0)
|
Self-constructed scale evaluated with the sum of scores (1-10) for 5 items (based on Nau & Borkovec, 1972).
The 5 items include rating the intervention's logic, satisfaction, recommendability, expected usefulness, and the respondent's readiness to follow it.
A higher score reflects a more positive expectation towards the upcoming intervention.
|
Clinical investigation day 1 (week 0)
|
|
Attitude towards intervention: Intervention opinion
Time Frame: Clinical investigation day 2 (week 12), Clinical investigation day 3 (week 24)
|
Self-constructed scale evaluated with the sum of scores (1-10) for 5 items (based on Nau & Borkovec, 1972).
The 5 items include rating the intervention's logic, satisfaction, recommendability, usefulness, and the respondent's readiness/intention to continue with it.
A higher score reflects a more positive opinion towards the experienced intervention.
|
Clinical investigation day 2 (week 12), Clinical investigation day 3 (week 24)
|
|
Attitude towards intervention: Dietetic tool acceptance (serving spoon, oil dispenser)
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), Clinical investigation day 3 (week 24)
|
Previously piloted questionnaire (Almiron-Roig et al., 2016) including 5-Pt Likert scores for portion tool attractiveness, fits within lifestyle, embarrassment, ease of use, perceived effectiveness and resistant to use.
An average score of 1 or 2 indicates low acceptance, 3 neutral, and 4 or 5 high acceptance.
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), Clinical investigation day 3 (week 24)
|
|
Attitude towards intervention: Intervention component acceptance (serving spoon, oil dispenser, intervention guide, intervention app)
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), Clinical investigation day 3 (week 24)
|
Single scale instrument measuring the level of intention to use each component from 0-100 on a 100 mm visual analogue scale (previously piloted questionnaire, Almiron-Roig et al., 2016).
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), Clinical investigation day 3 (week 24)
|
|
Attitude towards intervention: Perceived app usability
Time Frame: Clinical investigation day 2 (week 12), Clinical investigation day 3 (week 24)
|
System Usability Scale (SUS) (based on Brooke, 1996).
Includes ten 5-Pt Likert questions of which 5 items are scored positively (pleasant, easy to use, good functionality, quick to learn, safe), and 5 items are scored reversedly (complex, requires support, inconsistent, complicated to use, requires learning).
A higher overall score indicates higher perceived usability.
|
Clinical investigation day 2 (week 12), Clinical investigation day 3 (week 24)
|
|
Attitude towards intervention: Intervention guide assessment
Time Frame: Clinical investigation day 2 (week 12)
|
Self-constructed questionnaire including 20 items answered with a 5-Pt Likert scale.
The first 10 items assess content of the guide (credibility, coherence, usefulness, applicability) and the second 10 items assess format (organisation, word choice and communication style).
A score <60 indicates poor assessment (the tool cannot be used in clinical practice as it stands); a score between 60-79 indicates the tool needs revision before implementation; a score of 80 or above indicates the tool is well rated by potential users and may be useful in clinical practice.
|
Clinical investigation day 2 (week 12)
|
|
Intervention component usage: serving spoon
Time Frame: Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
Types of meals in which the serving spoons were most frequently used
|
Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
|
Intervention component usage: oil dispenser
Time Frame: Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
Types of meals in which the oil dispenser was most frequently used
|
Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
|
Intervention component usage: intervention guide
Time Frame: Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
Guide sections most frequently checked
|
Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
|
Intervention component usage: intervention app
Time Frame: Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
App functions most frequently used
|
Phone call (week 2, week 4, week 6, week 8, week 10); Clinical investigation day 2 (week 12); Phone call (week 14, week 16, week 18, week 20, week 22); Clinical investigation day 3 (week 24)
|
|
Protocol compliance on clinical investigation days
Time Frame: Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), Clinical investigation day 3 (week 24)
|
Self-constructed interview to verify participants' compliance with arrival time, physical activity and dietary requirements and any change in medication occurred prior to each clinical investigation day
|
Clinical investigation day 1 (week 0), Clinical investigation day 2 (week 12), Clinical investigation day 3 (week 24)
|
|
End of study survey
Time Frame: Clinical investigation day 3 (week 24)
|
Self-constructed interview to assess participant's overall experience with the intervention at study end (items include previous tools/methods employed, satisfaction with intervention, consistency of use, barriers experienced and intention to continue using the components)
|
Clinical investigation day 3 (week 24)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Eva Almiron-Roig, PhD, University of Navarra
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 14, 2024
Primary Completion (Estimated)
September 27, 2024
Study Completion (Estimated)
March 31, 2025
Study Registration Dates
First Submitted
May 16, 2024
First Submitted That Met QC Criteria
July 24, 2024
First Posted (Actual)
July 25, 2024
Study Record Updates
Last Update Posted (Actual)
July 25, 2024
Last Update Submitted That Met QC Criteria
July 24, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- PC139-140
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Weight Management
-
University of BaghdadNot yet recruiting
-
Azienda Ospedaliera Universitaria Policlinico Paolo...CompletedWeight ManagementItaly
-
Society for EndocrinologyEnrolling by invitationWeight ManagementUnited Kingdom
-
SF Research Institute, Inc.CompletedStress | Weight ManagementUnited States
-
National University Health System, SingaporeRecruiting
-
Wake Forest University Health SciencesCompleted
-
University of Massachusetts, WorcesterBoston University; National Institute of Diabetes and Digestive and Kidney... and other collaboratorsRecruitingWeight Management CounselingUnited States
-
UAS Labs LLCCompleted
-
Institut Pasteur de LilleCompletedWeight Management | Food ComplementFrance
-
The Hong Kong Polytechnic UniversityCompletedHealthy Diet | Weight ManagementHong Kong
Clinical Trials on PORTIONS-4 behaviour change strategies
-
University of WaterlooUniversity Health Network, Toronto; University of British Columbia; Canadian... and other collaboratorsCompleted
-
Liverpool John Moores UniversityUniversity of Liverpool; Dublin City UniversityUnknownExerciseIreland, United Kingdom
-
Sheffield Teaching Hospitals NHS Foundation TrustCompletedCystic FibrosisUnited Kingdom
-
University of British ColumbiaUniversity of Sao PauloNot yet recruiting
-
Sheffield Teaching Hospitals NHS Foundation TrustCompletedCystic FibrosisUnited Kingdom
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic ObstructiveUnited States
-
Wageningen UniversityRijnstate Hospital; Flevoziekenhuis; Deventer Ziekenhuis; World Cancer Research... and other collaboratorsCompletedColorectal Cancer | Rectal Cancer | Colon Cancer | Cancer-related FatigueNetherlands
-
The Hong Kong Polytechnic UniversityCompletedSarcopenic ObesityChina
-
King's College LondonCompleted
-
University of VictoriaCompletedPhysical Activity | Health PromotionCanada